Bisphosphonate Therapy with Zoledronate or Tenofovir Switching to Improve Low Bone Mineral Density in HIV-Infected Adults: a Strategic, Randomised Trial [ 2012 - 2015 ]

Research Grant

Researchers: Prof Andrew Carr (Principal investigator) ,  A/Pr Nicholas Pocock ,  Prof Jennifer Hoy ,  Prof Peter Ebeling

Brief description Most HIV+ Australians receive tenofovir, a ‘preferred’ drug in all HIV treatment guidelines, and may do for decades, as HIV therapy is lifelong and because there are very few new HIV drugs. 40% of HIV+ adults have low bone density and HIV+ adults experience more fractures. Of all HIV drugs, tenofovir causes the most bone loss. This trial compares two approaches: a drug to improve bone density and switching tenofovir to another drug. This ‘treat versus switch’ approach is a world-first for HIV.

Funding Amount $AUD 716,300.21

Funding Scheme Project Grants

Notes Standard Project Grant